Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Colorectal Cancer | Research

Comparative characteristics of early-onset vs. late-onset advanced colorectal cancer: a nationwide study in China

Authors: Hongwei Liu, Huifang Xu, Yin Liu, Yuqian Zhao, Xi Zhang, Yanqin Yu, Lingbin Du, Yunyong Liu, Wenjun Wang, Helu Cao, Li Ma, Juanxiu Huang, Ji Cao, Li Li, Yanping Fan, Xiaofen Gu, Changyan Feng, Qian Zhu, Xiaohui Wang, Jingchang Du, Shaokai Zhang, Youlin Qiao

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

The incidence of early-onset colorectal cancer (EOCRC, diagnosed in patients under the age of 50 years) has been increasing around the world. Here, we aimed to systematically identify distinctive features of EOCRC.

Methods

From 2020 to 2021, we conducted a nationwide survey in 19 hospitals, collecting data on advanced CRC patients’ demographics, clinical features, disease knowledge, medical experiences, expenditures, and health-related quality of life (HRQOL). We compared these features between EOCRC and late-onset colorectal cancer (LOCRC, ≥ 50 years old) groups and analyzed the association between EOCRC and HRQOL using multivariate linear regression.

Findings

In total, 991 patients with EOCRC and 3581 patients with LOCRC were included. Compared to the LOCRC group, the EOCRC group had higher levels of education, were more informed about the risk factors for CRC, were more likely to have widespread metastases throughout the body, were more inclined to undergo gene testing, and were more likely to opt for targeted therapy, radiotherapy, and chemotherapy. However, HRQOL in the EOCRC group was similar to that of the LOCRC group, and no significant association was observed between EOCRC and HRQOL (beta: -0.753, P value: 0.307).

Interpretation

In Chinese patients, EOCRC patients had more aggressive features. Despite undergoing more intensified treatments and gene testing, they had similar HRQOL compared with LOCRC. These findings advocate for a more tailored approach to treatment, especially for young CRC patients with advanced TNM stages and metastasis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed
2.
go back to reference Patel SG, Karlitz JJ, Yen T, Lieu CH, Boland CR. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7(3):262–74.CrossRefPubMed Patel SG, Karlitz JJ, Yen T, Lieu CH, Boland CR. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol. 2022;7(3):262–74.CrossRefPubMed
3.
go back to reference Siegel RL, Fedewa SA, Anderson WF et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109(8). Siegel RL, Fedewa SA, Anderson WF et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. J Natl Cancer Inst. 2017;109(8).
4.
go back to reference Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216–24.CrossRefPubMed Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216–24.CrossRefPubMed
5.
go back to reference Lui RN, Tsoi KKF, Ho JMW, et al. Global increasing incidence of Young-Onset Colorectal Cancer Across 5 continents: a Joinpoint Regression Analysis of 1,922,167 cases. Cancer Epidemiol Biomarkers Prev. 2019;28(8):1275–82.CrossRefPubMed Lui RN, Tsoi KKF, Ho JMW, et al. Global increasing incidence of Young-Onset Colorectal Cancer Across 5 continents: a Joinpoint Regression Analysis of 1,922,167 cases. Cancer Epidemiol Biomarkers Prev. 2019;28(8):1275–82.CrossRefPubMed
6.
go back to reference Cercek A, Chatila WK, Yaeger R, et al. A Comprehensive comparison of early-onset and average-onset colorectal cancers. J Natl Cancer Inst. 2021;113(12):1683–92.CrossRefPubMedPubMedCentral Cercek A, Chatila WK, Yaeger R, et al. A Comprehensive comparison of early-onset and average-onset colorectal cancers. J Natl Cancer Inst. 2021;113(12):1683–92.CrossRefPubMedPubMedCentral
7.
go back to reference Gao XH, Li J, Liu LJ, et al. Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: a retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center. Int J Surg. 2022;104:106780.CrossRefPubMed Gao XH, Li J, Liu LJ, et al. Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: a retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center. Int J Surg. 2022;104:106780.CrossRefPubMed
8.
go back to reference Chen Y, Chen Z, Huang J, et al. Clinicopathological and molecular characteristics of early-onset vs late-onset colorectal cancer according to tumor location. Int J Clin Oncol. 2022;27(4):749–55.CrossRefPubMed Chen Y, Chen Z, Huang J, et al. Clinicopathological and molecular characteristics of early-onset vs late-onset colorectal cancer according to tumor location. Int J Clin Oncol. 2022;27(4):749–55.CrossRefPubMed
9.
go back to reference Kirzin S, Marisa L, Guimbaud R, et al. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PLoS ONE. 2014;9(8):e103159.CrossRefPubMedPubMedCentral Kirzin S, Marisa L, Guimbaud R, et al. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PLoS ONE. 2014;9(8):e103159.CrossRefPubMedPubMedCentral
10.
go back to reference Watson R, Liu TC, Ruzinova MB. High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. Hum Pathol. 2016;56:163–70.CrossRefPubMed Watson R, Liu TC, Ruzinova MB. High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. Hum Pathol. 2016;56:163–70.CrossRefPubMed
11.
go back to reference Liu Y, Xu HF, Zhang X, et al. Disease knowledge, medical experience, health-related quality of life and health-care costs among patients with advanced colorectal cancer in China: protocol for a nationwide multicentre survey. BMJ Open. 2022;12(3):e054403.CrossRefPubMedPubMedCentral Liu Y, Xu HF, Zhang X, et al. Disease knowledge, medical experience, health-related quality of life and health-care costs among patients with advanced colorectal cancer in China: protocol for a nationwide multicentre survey. BMJ Open. 2022;12(3):e054403.CrossRefPubMedPubMedCentral
12.
go back to reference [Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer]. Zhonghua Wai Ke Za Zhi. 2018;56(4):241–58. [Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer]. Zhonghua Wai Ke Za Zhi. 2018;56(4):241–58.
13.
go back to reference [China guideline for the. Screening, early detection and early treatment of colorectal cancer (2020, Beijing)]. Zhonghua Zhong Liu Za Zhi. 2021;43(1):16–38. [China guideline for the. Screening, early detection and early treatment of colorectal cancer (2020, Beijing)]. Zhonghua Zhong Liu Za Zhi. 2021;43(1):16–38.
14.
go back to reference Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.CrossRefPubMed Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.CrossRefPubMed
15.
go back to reference Wong CK, Lam CL, Law WL, et al. Validity and reliability study on traditional Chinese FACT-C in Chinese patients with colorectal neoplasm. J Eval Clin Pract. 2012;18(6):1186–95.CrossRefPubMed Wong CK, Lam CL, Law WL, et al. Validity and reliability study on traditional Chinese FACT-C in Chinese patients with colorectal neoplasm. J Eval Clin Pract. 2012;18(6):1186–95.CrossRefPubMed
16.
go back to reference Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30). J Epidemiol. 2004;14(6):193–203.CrossRefPubMed Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30). J Epidemiol. 2004;14(6):193–203.CrossRefPubMed
17.
go back to reference Cheng JX, Liu BL, Zhang X, et al. The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Med Res Methodol. 2011;11:56.CrossRefPubMedPubMedCentral Cheng JX, Liu BL, Zhang X, et al. The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Med Res Methodol. 2011;11:56.CrossRefPubMedPubMedCentral
18.
go back to reference Vuik FER, Nieuwenburg SAV, Nagtegaal ID, Kuipers EJ, Spaander MCW. Clinicopathological characteristics of early onset colorectal cancer. Aliment Pharmacol Ther. 2021;54(11–12):1463–71.CrossRefPubMedPubMedCentral Vuik FER, Nieuwenburg SAV, Nagtegaal ID, Kuipers EJ, Spaander MCW. Clinicopathological characteristics of early onset colorectal cancer. Aliment Pharmacol Ther. 2021;54(11–12):1463–71.CrossRefPubMedPubMedCentral
19.
go back to reference Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced-Stage Colorectal Cancer in persons younger than 50 years not Associated with longer duration of symptoms or time to diagnosis. Clin Gastroenterol Hepatol. 2017;15(5):728–e737723.CrossRefPubMed Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced-Stage Colorectal Cancer in persons younger than 50 years not Associated with longer duration of symptoms or time to diagnosis. Clin Gastroenterol Hepatol. 2017;15(5):728–e737723.CrossRefPubMed
20.
go back to reference Messersmith WA. NCCN guidelines updates: management of metastatic colorectal Cancer. J Natl Compr Canc Netw. 2019;17(55):599–601.PubMed Messersmith WA. NCCN guidelines updates: management of metastatic colorectal Cancer. J Natl Compr Canc Netw. 2019;17(55):599–601.PubMed
21.
go back to reference Dong C, Ding Y, Weng S, et al. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. Chin J Cancer Res. 2021;33(3):302–7.CrossRefPubMedPubMedCentral Dong C, Ding Y, Weng S, et al. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. Chin J Cancer Res. 2021;33(3):302–7.CrossRefPubMedPubMedCentral
22.
go back to reference Kneuertz PJ, Chang GJ, Hu CY, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015;150(5):402–9.CrossRefPubMed Kneuertz PJ, Chang GJ, Hu CY, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015;150(5):402–9.CrossRefPubMed
23.
go back to reference Zaborowski AM, Abdile A, Adamina M, et al. Characteristics of early-onset vs late-onset colorectal Cancer: a review. JAMA Surg. 2021;156(9):865–74.CrossRefPubMed Zaborowski AM, Abdile A, Adamina M, et al. Characteristics of early-onset vs late-onset colorectal Cancer: a review. JAMA Surg. 2021;156(9):865–74.CrossRefPubMed
24.
go back to reference Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer. 2016;122(6):929–34.CrossRefPubMed Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer. 2016;122(6):929–34.CrossRefPubMed
25.
go back to reference Saraste D, Järås J, Martling A. Population-based analysis of outcomes with early-age colorectal cancer. Br J Surg. 2020;107(3):301–9.CrossRefPubMed Saraste D, Järås J, Martling A. Population-based analysis of outcomes with early-age colorectal cancer. Br J Surg. 2020;107(3):301–9.CrossRefPubMed
26.
go back to reference Zaborowski AM, Murphy B, Creavin B, et al. Clinicopathological features and oncological outcomes of patients with young-onset rectal cancer. Br J Surg. 2020;107(5):606–12.CrossRefPubMed Zaborowski AM, Murphy B, Creavin B, et al. Clinicopathological features and oncological outcomes of patients with young-onset rectal cancer. Br J Surg. 2020;107(5):606–12.CrossRefPubMed
27.
go back to reference Eng C, Jácome AA, Agarwal R, et al. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 2022;23(3):e116–28.CrossRefPubMed Eng C, Jácome AA, Agarwal R, et al. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 2022;23(3):e116–28.CrossRefPubMed
28.
go back to reference Roberts RO, Bergstralh EJ, Schmidt L, Jacobsen SJ. Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol. 1996;49(9):989–95.CrossRefPubMed Roberts RO, Bergstralh EJ, Schmidt L, Jacobsen SJ. Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol. 1996;49(9):989–95.CrossRefPubMed
Metadata
Title
Comparative characteristics of early-onset vs. late-onset advanced colorectal cancer: a nationwide study in China
Authors
Hongwei Liu
Huifang Xu
Yin Liu
Yuqian Zhao
Xi Zhang
Yanqin Yu
Lingbin Du
Yunyong Liu
Wenjun Wang
Helu Cao
Li Ma
Juanxiu Huang
Ji Cao
Li Li
Yanping Fan
Xiaofen Gu
Changyan Feng
Qian Zhu
Xiaohui Wang
Jingchang Du
Shaokai Zhang
Youlin Qiao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12278-7

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine